Neurotechnology industry revenues reach $120.5 billion
4 June 2007
San Francisco, USA. A survey of the neurotechnology
industry has found that total revenues from pharmaceuticals, devices and
diagnostics reached $120bn worldwide in 2006.
The Neurotechnology Industry 2007 Report: Drugs, Devices and
Diagnostics for the Brain and Nervous System, produced by NeuroInsights,
is a market analysis and strategic investment guide of the global
neurological disease and psychiatric illness markets. The report focuses on
the more than 500 public and private companies producing neurotechnology
The report provides an in-depth look at fifteen brain and
central nervous system disorders, including Alzheimer's disease, addiction,
anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia,
memory decline, obesity, pain, Parkinson's, psychiatric disorders, stroke
and other brain-related illnesses.
Specific findings from the
Neurotechnology Industry 2007 Report include:
- Brain-related illnesses afflict more than two billion people
- The worldwide economic burden of this problem has reached more than
$2 trillion per year; more than $1 trillion in the USA alone.
- 2006 venture capital investment in neurotechnology rose 7.5% to
- Neurotech industry revenues rose 10% in 2006 to $120.5 billion; this
includes neuropharmaceutical revenues of $101 billion, neurodevice
revenues of $4.5 billion, neurodiagnostic revenues of $15 billion.
- The Neurotech Index of publicly-traded neurotechnology companies was
up 53% from its December 31, 2003 conception to March 31, 2006,
outpacing the NASDAQ Biotech Index which gained 7% during the same
"Neurotechnology is still very much a frontier industry," said Zack
Lynch, founder of NeuroInsights and Executive Director of the
Neurotechnology Industry Organization.
"In the past year we've reached some important milestones, including
formation of NIO, the first industry organization devoted to the
specific needs of neurotechnology companies. 2006 was also a tremendous
year of growth for the industry, and 2007 looks to continue this trend
so as technologies improve and our collective body of knowledge grows.
"Countless opportunities exist as visionary researchers tackle the
complexities of brain-related health and visionary companies,
organizations and policy makers address the complexities of bringing
those discoveries to the billions of people suffering from brain-related